Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clearmind MedicineFRA:CWY0 22 Receivables Turnover is 0.00 as of Apr. 2026. GuruFocus rates FRA:CWY0 with a GF Score™ of 22/100. The stock has 1 warning sign investors should review. Among 842 Biotechnology companies, Clearmind Medicine ranks worse than 118764.73% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Clearmind Medicine's Revenue for the
three
months ended in Apr. 2026 was €0.00 Mil. Clearmind Medicine's average Accounts Receivable for the
three
months ended in Apr. 2026 was €0.00 Mil.
Clearmind Medicine (FRA:CWY0) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Clearmind Medicine Receivables Turnover Related Terms
Clearmind Medicine Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Clearmind Medicine's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:CWY0 vs SLXN, OGEN, GRI: Receivables Turnover Comparison
For the Biotechnology subindustry, Clearmind Medicine's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clearmind Medicine Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clearmind Medicine's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Clearmind Medicine's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clearmind Medicine (FRA:CWY0) has a Receivables Turnover of 0.00 as of Apr. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Clearmind Medicine and its competitors. According to the industry distribution chart, Clearmind Medicine ranks #999999 out of 842 companies in the Biotechnology industry.
Is Clearmind Medicine's Receivables Turnover too high?
Clearmind Medicine's current Receivables Turnover is 0.00. Based on the distribution chart, Clearmind Medicine ranks #999999 out of 842 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Clearmind Medicine has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Clearmind Medicine's Receivables Turnover compare to SLXN and OGEN?
According to the Biotechnology industry distribution chart, Clearmind Medicine ranks #999999 out of 842 companies for Receivables Turnover. This places Clearmind Medicine in the lower half of its industry. The industry median Receivables Turnover is 5.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Clearmind Medicine and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clearmind Medicine's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clearmind Medicine stock overvalued right now?
Clearmind Medicine (FRA:CWY0) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. Clearmind Medicine's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Clearmind Medicine (FRA:CWY0), the current Receivables Turnover is 0.00 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
22GF Score
Get the complete analysis for FRA:CWY0
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:CWY0 has been successfully added to your 
